Aclaris Therapeutics

ACRS:NAS

Pharmaceuticals: Other

Market Cap

—

SMALL cap

Share Price ←

(—)

YTD Return ←

—

since start of 2021

P/E Ratio

—

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

About

Pharmaceuticals: Other Founded 2012

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in identifying, developing and commercializing novel drugs to address unmet needs in dermatology. It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

website

Headquarters

Suite 400

101 Lindenwood Drive

Malvern, PA 19355

1.484.324.7933

Executives

Name	Title	Gender
Neal S. Walker, PhD, MBA	President, Chief Executive Officer & Director	Male
Michael Stephen Tung, MD, MBA	Vice President-Investor Relations	Male
Stephen A. Tullman	Chairman	Male
Kamil Ali-Jackson	Chief Legal Officer	Female
Frank Ruffo, CPA	Chief Financial Officer	Male
Christopher V. Powala	Chief Operating Officer	Male
Stuart D. Shanler, MD	Chief Scientific Officer	Male

Mindful Investing Summary

Carbon Footprint

— N/A
Pollution Prevention

— N/A
Water Conservation

— N/A
Data & Privacy Protection

— N/A
Consumer Health, Wellness & Safety

— N/A
Employee Ownership, Satisfaction, Benefits & Pay

— N/A
Workplace Health and Safety

— N/A
Integrity of Corporate Governance

— N/A
Ethical Practices

— N/A
Usage of Conflict Materials

— N/A
Forced Labor

— N/A
Diversity of Corporate Leadership

2 N/A

Aclaris Therapeutics - Competitors and Related Companies

How Aclaris Therapeutics stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.